The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.

Cost effectiveness and resource allocation : C/E

GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.

Appetite

Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.

Diabetes & metabolic syndrome

Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.

PloS one

Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study.

Metabolites

Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk.

Cells

A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.

Cureus

Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).

Diabetes, obesity & metabolism

🚨 $HIMS CHIEF MEDICAL OFFICER, ANANT VINJAMOORI, AT THE FDA PEPTIDES MEETING: "My company [Hims & Hers] intends to offer peptide therapy if allowed. We intend to do so with guardrails because we think that is in the best interest of patients." "We would, in fact, benefit https://t.co/bR3aUJC27D https://t.co/KyMuYsXyDL

I've tested over 100 compounds since 2017 (peptides, shrooms, TRT, nicotine, etc.) to improve my health, performance, and focus. A short list of the ones that made the greatest impact: 1) GLP-1s (the heaviest hitters I've ever used) - Retatrutide - Tirzepatide - Semaglutide

🚨 The next bull 🐂 market will be longevity with peptides and $HIMS & $ENHA are at the very forefront of this new market. • The global peptide therapeutics market size is projected to grow from USD 164.0 billion in 2026 to USD 294.6 billion by 2033, at a CAGR of 8.7% from 2026 https://t.co/1JdUEXGX9Q

Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 to the 503A Bulks List for use in compounding for ulcerative colitis. While this is only a recommendation and not a final https://t.co/aqHs90MxkF

🚨 BPC-157 and KPV just received favorable PCAC votes for the 503A Bulk Drug Substances List - 2 of 7 peptides now recommended ✅ Today on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) delivered important non-binding recommendations during day one of https://t.co/iNlQaFx9lH

Some acronyms you’ll see a lot in peptide discussions and what they mean: API: Active Pharmaceutical Ingredient = Basically the actual active peptide as opposed to fillers, stabilizers, or BAC water. Often used loosely to mean "the raw powder," though the powder isn't always

https://t.co/7bn4aYBY06

Hims & Hers $HIMS: FDA Peptide Vote Could Mark the Start of a New Healthcare Category Hims & Hers $HIMS rallied after an FDA advisory committee voted 8-6 to recommend adding BPC-157 to the 503A Bulks List, potentially allowing licensed compounding pharmacies to prepare the https://t.co/fGRtWgcCBA